China’s medical regulator has approved Brii Biosciences’ antibody combination Covid-19 treatment for adults and adolescents, making it the first therapy of this kind given the green light in the country.
The BRII-196/BRII-198 combination is intended to treat mild Covid-19 and “common types” of the disease in patients with high risk of developing severe illness, the National Medical Products Administration said in a statement.
Continue reading https://on.rt.com/bmo9